Experimental Alzheimer’s drug slows cognitive decline in trial, firms say
Makers of the drug have already applied to the Food and Drug Administration for accelerated approval for lecanemab, based on earlier-stage data.
Source: Washington Post: To Your Health - Category: Consumer Health News Authors: Laurie McGinley Source Type: news
More News: Food and Drug Administration (FDA) | Health